<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00099788</url>
  </required_header>
  <id_info>
    <org_study_id>CVT 3036</org_study_id>
    <secondary_id>MERLIN TIMI 36</secondary_id>
    <nct_id>NCT00099788</nct_id>
  </id_info>
  <brief_title>Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multinational, Clinical Trial to Evaluate the Efficacy and Safety of Ranolazine vs Placebo in Patients With Non-ST Segment Elevation Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The TIMI Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled,
      parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine
      during acute and long-term treatment in approximately 5,500 patients with non-ST elevation
      acute coronary syndromes (ACS) treated with standard therapy. The primary efficacy endpoint
      in MERLIN-TIMI 36 is time to first occurrence of any element of the composite of
      cardiovascular death, myocardial infarction or recurrent ischemia in patients with non-ST
      elevation ACS receiving standard therapy. The study also evaluates the safety of long-term
      treatment with ranolazine compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI
      36 Investigators. Evaluation of a novel anti-ischemic agent in acute coronary syndromes:
      design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in
      Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J. 2006
      Jun;151(6):1186.e1-9.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction or recurrent ischemia through the end of the follow-up in non-ST elevation ACS.</measure>
    <time_frame>First occurrence</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiovascular death, myocardial infarction, or severe recurrent ischemia. Safety of long-term treatment with ranolazine compared to placebo; safety endpoints are death from any cause and symptomatic documented arrhythmia.</measure>
    <time_frame>First occurence</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6560</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>IV to oral transition.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV to oral transition.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized with non-ST elevation acute coronary syndrome

          -  Ischemic symptoms (more than or equal to 5 minutes) at rest within 48 hours of study
             entry

          -  At least one additional risk factor (e.g., elevated cardiac enzymes, ST-depression,
             diabetes)

        Exclusion Criteria:

          -  Persistent acute ST-segment elevation

          -  Successful revascularization during the qualifying hospitalization, prior to study
             entry

          -  Acute pulmonary edema, hypotension, or evidence of cardiogenic shock

          -  Clinically significant liver disease

          -  End stage kidney disease requiring dialysis

          -  Concomitant use of drugs known to prolong the QT interval, or any digitalis drugs

          -  Use at study entry of drugs that are strong inhibitors of cytochrome P450 3A4

          -  Pregnant or lactating women, or women of child bearing potential not using an
             acceptable form of birth control

        Additional study entry criteria will be evaluated during initial screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Morrow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TIMI Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The TIMI Study Group</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.timi.org</url>
  </link>
  <reference>
    <citation>Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Investigators. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J. 2006 Jun;151(6):1186.e1-9.</citation>
    <PMID>16781216</PMID>
  </reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2004</study_first_submitted>
  <study_first_submitted_qc>December 20, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2004</study_first_posted>
  <last_update_submitted>November 24, 2009</last_update_submitted>
  <last_update_submitted_qc>November 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Philip Sager, Vice President, Clinical Research</name_title>
    <organization>Gilead Sciences</organization>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Heart Attack</keyword>
  <keyword>Angina</keyword>
  <keyword>Chest pain</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Non-ST Elevation Acute Coronary Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

